EnRich Financial Partners’s Johnson & Johnson JNJ Stock Holding History

EnRich Financial Partners’s Portfolio JNJ Stock Details JNJ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-630	Closed	-$91.1K	–	141
2024 Q4	$91.1K	Hold	630	–	–	0.03%	80
2024 Q3	$102K	Buy	630 +1	+0.2%	+$159	0.03%	75
2024 Q2	$92K	Hold	629	–	–	0.03%	76
2024 Q1	$99.5K	Buy	+629	New	+$100K	0.04%	70

Other funds holding JNJ

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

EnRich Financial Partners's JNJ Position: Q1 2025 in Review

EnRich Financial Partners sold out of Johnson & Johnson (JNJ) in Q1 2025, closing a stake of 630 shares — an estimated $91.1K sold.

EnRich Financial Partners first reported a position in JNJ in Q1 2024 and held it in 4 quarters. The position peaked at $102K in Q3 2024. 4,148 funds tracked by Wall St. Rank hold JNJ as of Q1 2025.

EnRich Financial Partners reported no remaining Johnson & Johnson position as of Q1 2025 after selling out during the quarter.
EnRich Financial Partners sold 630 Johnson & Johnson shares in Q1 2025, an estimated $91.1K.
EnRich Financial Partners first reported a position in Johnson & Johnson in Q1 2024 and held it in 4 quarters.
EnRich Financial Partners's Johnson & Johnson position peaked at $102K in Q3 2024.
4,148 funds tracked by Wall St. Rank held Johnson & Johnson as of Q1 2025.

Based on EnRich Financial Partners's 13F filing for Q1 2025, filed 25 Apr 2025.